Multispan believes innovation is a critical part of driving improvement across the drug discovery and development
pipeline — from promoting a deeper understanding of target biology, to identifying higher quality leads in less time, to
producing more physiologically relevant data for improved clinical translation. Our dedication to innovation is
evidenced through our unique approaches to recombinant expression of membrane proteins and novel assay
technologies which have led to over 30 patents.
Multispan recognized the need for improved β-Arrestin screening assays and developed a novel HTS technology, MULTISCREEN™ β-Arrestin Sensor technology, that can assess β-Arrestin signaling of native GPCRs in recombinant or primary cells – a critical aspect for assessing receptor physiology.
Our assay kits, reagents and services based on MULTISCREEN™ β-Arrestin sensor technology enable researchers to examine unmodified GPCRs, including endogenously expressed GPCR targets, which provide more relevant data for
improved identification and optimization of qualified drug candidates.
Control and eradication of SARS-Cov-2 will require advanced antivirals and/or a protective vaccine – development of both of which depends on improved knowledge of the virus pathophysiology, identification and therapeutic exploitation of the vulnerabilities of the virus, and characterization of the components of protective immunity.
Multispan has a proven record of complex cell engineering and assay development. Ensure the advancement of your SARS-CoV-2 drug and vaccine development efforts by harnessing the knowledge and expertise of their scientific teams. Contact Multispan today to discuss the design and implementation of your COVID assay.
Multispan developed a proprietary technology to enable expression of GPCR proteins in mammalian cells at over a
million molecules per cell surface. High expressing cells (HEx™) can be developed into single cell clones and used as a
unique source of high quality GPCR proteins for variety of applications: